CAMBRIDGE, Mass., Nov. 2, 2011 /PRNewswire/ -- Quanterix Corporation, a company enabling a new generation of molecular diagnostic tests based on its revolutionary Single Molecule Array (SiMoA™) technology, announced that the analytical performance of its Prostate Specific Antigen (PSA) test, a fifth-generation digital immunoassay, demonstrated a 2-log improvement in sensitivity over today's ultrasensitive third-generation PSA assays used to measure PSA levels in patients following radical prostatectomy. The results were published online by Clinical Chemistry.
"Quanterix has developed and validated a test that enables reliable measurements of PSA in men who have undergone radical prostatectomy for prostate cancer. Following surgery, PSA levels typically drop to 'undetectable' with conventional third-generation tests, but we were able to accurately measure PSA with high precision in all samples evaluated," stated David Wilson Ph.D., Senior Director, Product Development at Quanterix and lead author of the study. The analytical performance of this assay is further highlighted in the publication, and complements clinical data that has recently been published which suggests this test is a reliable predictor of five-year biochemical recurrence-free survival following surgery. Dr. Wilson continued, "Increasing evidence suggests that a more sensitive PSA assay could improve patient prognosis and inform clinical decisions for use of secondary therapy in individuals who have been treated surgically."
"Quanterix is developing a menu of high quality thoroughly characterized assays that will demonstrate the value of our SiMoA platform in both the life sciences and in vitro diagnostics markets. These results provide another great example of how transformative sensitivity will allow us to deliver on the promise of next generation digital molecular diagnostics," said Martin Madaus, Ph.D., Chairman and
|SOURCE Quanterix Corporation|
Copyright©2010 PR Newswire.
All rights reserved